Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Metabolic Enzyme Stops Renal Cancer Progression

July 22, 2014 10:52 am | News | Comments

In an analysis of small molecules called metabolites used by the body to make fuel in normal and cancerous cells in human kidney tissue, a research team from the Perelman School of Medicine at the University of Pennsylvania identified an enzyme key to applying the brakes on tumor growth. Read more...

TOPICS:

Genetic Mapping Triggers Hope for Schizophrenia

July 22, 2014 10:40 am | by Seth Borenstein, AP Science Writer | News | Comments

Scientists have linked more than 100 spots in our DNA to the risk of developing schizophrenia, casting light on the mystery of what makes the disease tick, providing the first hard genetic evidence to bolster a theory connecting the immune system to the disease. Read more...

TOPICS:

NIH Grants Sorrento Funding for Development of Small Molecule Inhibitor

July 21, 2014 3:57 pm | News | Comments

Sorrento Therapeutics Inc. announced that it has received non-dilutive funding for the preclinical development of a small molecule inhibitor targeting the important oncogenic transcription factor Myc. Read more…           

TOPICS:
Advertisement

FDA Accepts Avanir's Trial App for Depression Drug

July 21, 2014 3:43 pm | News | Comments

Avanir Pharmaceuticals Inc. announced that the FDA accepted the company's Investigational New Drug (IND) application for a Phase 2 study assessing the safety and efficacy of AVP-786, Avanir's next generation compound. Read more...      

TOPICS:

Dipexium Launches Phase 3 Trial of Foot Ulcer Antibiotic

July 21, 2014 3:37 pm | News | Comments

Dipexium Pharmaceuticals Inc. announced it has initiated patient enrollment in the second of two pivotal Phase 3 clinical trials, known as OneStep-1 and OneStep-2, evaluating Locilex for the treatment of patients with mild infections of diabetic foot ulcers. Read more...

TOPICS:

Arena Grants Marketing, Supply Rights for Belviq in Israel

July 21, 2014 3:28 pm | News | Comments

Arena Pharmaceuticals GmbH has entered into an exclusive marketing and supply agreement for Belviq (lorcaserin HCl) with Teva Pharmaceutical Industries Ltd.'s local Israeli subsidiary, Abic Marketing Limited. Read more...         

TOPICS:

Antipsychotic Drugs Linked to Decreased Brain Volume

July 21, 2014 3:18 pm | News | Comments

A new study has confirmed a link between antipsychotic medication and a slight, but measureable, decrease in brain volume in patients with schizophrenia. Read more...                        

TOPICS:

Gold Nanoparticles Penetrate Cells, Show Promise for Drug Delivery

July 21, 2014 3:09 pm | Videos | Comments

A special class of tiny gold particles can easily slip through cell membranes, making them good candidates to deliver drugs directly to target cells. Read more...                          

TOPICS:
Advertisement

MetaMax Enrolls First Patients in Trial of Anticancer Drug

July 21, 2014 11:58 am | News | Comments

The first patients have been enrolled in a Phase 1/2a clinical trial of a promising approach to treat malignant neoplasms. Following approval by the Russian Ministry of Health, Russian biotechnology company MetaMax will begin the trial of its lead anticancer compound MM-D37K. Read more...

TOPICS:

First Patients Enrolled in Trial of Opioid Dependence Treatment

July 21, 2014 11:49 am | News | Comments

Braeburn Pharmaceuticals announced that the first patients have been enrolled in its Phase 3 clinical study of Probuphine, a subdermal implant for the maintenance treatment of opioid dependence, for which there is an acute need for innovative and effective treatment options. Read more...

TOPICS:

Combo Therapy Cures Hep C in Co-Infected HIV Patients

July 21, 2014 11:37 am | News | Comments

A multicenter team of researchers report that in a Phase 3 clinical trial, a combination drug therapy — sofosbuvir and ribavirin — cures chronic hepatitis C in the majority of patients co-infected with both HIV and hepatitis C. Read more...

TOPICS:

China’s FDA Approves Conduct of Breast Cancer Trial

July 21, 2014 11:31 am | News | Comments

CASI Pharmaceuticals Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced that China's Food and Drug Administration has approved the company's application to conduct a Phase 2 clinical trial in triple-negative breast cancer patients in China for its proprietary drug candidate, ENMD-2076. Read more...

TOPICS:

Researchers Aim to Help Doctors Attack Metastases

July 21, 2014 11:22 am | News | Comments

Researchers at the University of Arkansas have been awarded $1.5 million from the National Cancer Institute at the National Institutes of Health to develop new molecules and biopharmaceuticals that enhance a patient’s immune response against tumors. Read more...

TOPICS:

Allergan to Cut 1,500 Employees in Restructuring

July 21, 2014 11:10 am | by Tom Murphy, AP Business Writer | News | Comments

Botox maker Allergan will cut about 13% of its workforce, or roughly 1,500 employees, as part of a push to become more efficient and productive, and in the takeover battle's latest twist, Valeant said Monday it has complained to regulators that Allergan has been making false statements about its business. Read more...

TOPICS:

JDRF, ViaCyte File IND App for Diabetes Treatment Trial

July 18, 2014 3:30 pm | News | Comments

JDRF announced that ViaCyte Inc. has filed an Investigational New Drug application (IND) with the FDA seeking to initiate a Phase 1/2 clinical trial in patients with type 1 diabetes. Read more...                

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading